-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Benzinga·03/30/2026 11:58:30
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.